A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD)
NCT07787650 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2026-08-26
Summary
The primary purpose of this study is to evaluate the safety and tolerability profile of S-606001 in participants with LOPD.
Conditions
Interventions
- DRUG
-
S-606001
S-606001 will be administered orally as a tablet.
Sponsors & Collaborators
-
Shionogi
lead INDUSTRY
Principal Investigators
-
Medical Director · Shionogi Inc.
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-09-30
- Primary Completion
- 2028-10-31
- Completion
- 2028-10-31
- FDA Drug
- Yes
More Related Trials
-
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD
NCT06666413 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate Emapalumab in Japanese Healthy Volunteers.
NCT04765553 ·Status: COMPLETED ·Phase: PHASE1
-
A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
NCT02618512 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
NCT07354724 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
NCT00782561 ·Status: TERMINATED ·Phase: PHASE1
-
Intracerebral Gene Therapy for Sanfilippo Type A Syndrome
NCT01474343 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
NCT03231878 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
NCT02603562 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Treatment Study of Mucopolysaccharidosis Type IIIB
NCT02754076 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy Patients
NCT07767890 ·Status: NOT_YET_RECRUITING
-
Gene Transfer Study in Patients With Late Onset Pompe Disease
NCT04174105 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)
NCT01924845 ·Status: TERMINATED ·Phase: PHASE3
-
Study of SOM0226 in Familial Amyloid Polyneuropathy
NCT02191826 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD
NCT07435129 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
NCT05630066 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE
NCT05492799 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
NCT04093349 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of JR-171 in Patients With Mucopolysaccharidosis I
NCT04227600 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I
NCT02702115 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
NCT05004129 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA
NCT04201405 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
NCT02000440 ·Status: COMPLETED ·Phase: PHASE2
-
Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2
NCT03505099 ·Status: COMPLETED ·Phase: PHASE3